SNOA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Sonoma Pharmaceuticals Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 1.10 USD
-3.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -44.0% below the Trend Line and sits at 4.1% of its 52-week range. The latest completed week returned -3.5%, after a -9.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 5d.

Setup score 19 out of 100
Latest Close 1.10 USD 31 Jul 2026
1W Return -3.5% latest completed week
4W Return -9.1% short-term follow-through
12W Return -8.3% quarterly tape
Trend Breadth 26.9% 14 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.94% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -3.5% Latest completed week; four-week move -9.1%. Indicator stack 15/60 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.94% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 39 relevant articles in the latest sentiment read. Event risk 5d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -44.0% below the Trend Line and sits at 4.1% of its 52-week range. The latest completed week returned -3.5%, after a -9.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0912-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.09Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -9.1% over four weeks, -8.3% over 12 weeks, and -63.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-3.5%
4W-9.1%
12W-8.3%
26W-66.5%
52W-63.2%
Active trend streak0 weeks
Active weeks in one year14
Trend breadth26.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.06Latest activity-pressure read.
Pressure change108.0%Four-week change in activity pressure.
Leadership-65.08Latest relative-leadership reading.
RS change0.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength37/100Blend of value, momentum, and quality. Underlying universe rank 64; rank 1 is best.
Value44/100Relative valuation strength. Underlying universe rank 57; rank 1 is best.
Quality42/100Profitability and accounting quality. Underlying universe rank 59; rank 1 is best.
Momentum44/100Medium-term price momentum. Underlying universe rank 57; rank 1 is best.
Growth44/100Revenue and earnings growth. Underlying universe rank 57; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-81.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
38.0%
Gross profit retained from each unit of revenue.
Operating margin
-12.6%
Operating profit retained from revenue.
Free-cash-flow margin
-16.2%
Free cash flow generated from revenue.
Return on invested capital
-120.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
36.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-853.3%
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-7.8%
Net share repurchases relative to market value.
Shareholder yield
-7.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 39 relevant articles.

4 positive · 30 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings5dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-84.1%Distance below the 52-week high.
13-week volatility4.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2614 weeks finished lower.
Best week+11.3%Week of 3 Apr.
Worst week-50.4%Week of 24 Apr.
Latest week-3.5%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains4
Flat weeks2
Modest losses6
Sharp losses8
Recent vol4.8%13-week weekly-return volatility.
Base vol13.8%52-week weekly-return volatility.
Up/down split23/27Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -7.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis12/100

Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.

Activity pressure 0.09; No reversal markers Next-Week ExpectancyNegative 42.94%

Next-week expectancy is negative with a 42.94% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors40/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 85 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 39 relevant articles.

SNOA|Sonoma Pharmaceuticals Inc|Price:1.100|Chg%:-0.040 Insiders6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings5d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.10 USD-3.5%1.96 USD4.13 USD0.06-65.08148.3KOff
24 Jul 20261.14 USD-5.8%2.05 USD4.26 USD-0.02-64.18122.9KOff
17 Jul 20261.21 USD-4.0%2.13 USD4.39 USD-0.19-63.26255.0KOff
10 Jul 20261.26 USD4.1%2.21 USD4.53 USD-0.40-64.01617.8KOff
3 Jul 20261.21 USD8.0%2.29 USD4.67 USD-0.71-65.481.2MOff
26 Jun 20261.12 USD-2.6%2.36 USD4.80 USD-1.14-68.23169.6KOff
19 Jun 20261.15 USD5.5%2.44 USD4.93 USD-1.38-69.281.6MOff
12 Jun 20261.09 USD-4.4%2.50 USD5.07 USD-1.52-70.58332.6KOff
5 Jun 20261.14 USD0.0%2.58 USD5.22 USD-1.58-69.02713.0KOff
29 May 20261.14 USD3.6%2.67 USD5.40 USD-1.59-70.92450.8KOff
22 May 20261.10 USD0.9%2.76 USD5.51 USD-1.57-71.661.1MOff
15 May 20261.09 USD-9.2%2.85 USD5.63 USD-1.60-72.05417.1KOff
8 May 20261.20 USD0.0%2.94 USD5.74 USD-1.57-69.82503.0KOff
1 May 20261.20 USD5.3%3.04 USD5.86 USD-1.50-68.681.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.